Back to Archived Journals » Botanics: Targets and Therapy » Volume 3

Plant-derived acetylcholinesterase inhibitory alkaloids for the treatment of Alzheimer's disease

Authors Dall'Acqua S

Received 18 February 2012

Accepted for publication 26 September 2012

Published 11 January 2013 Volume 2013:3 Pages 19—28

DOI https://doi.org/10.2147/BTAT.S17297

Review by Single-blind

Peer reviewer comments 2


Stefano Dall'Acqua

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

Abstract: The inhibition of acetylcholinesterase (AChE) has been one of the most used strategies for the treatment of Alzheimer's disease (AD). The AChE inhibitors (AChE-I) produce not only short-term symptomatic effects, but can also play a role in other pathological mechanisms of the disease (eg, formation of amyloid-β plaques), which has renewed interest in the discovery of such inhibitors. Four of the five currently prescribed treatments for AD are AChE-I. Natural alkaloids such as galantamine or alkaloid-related synthetic compounds (such as rivastigmine) are considered beneficial for patients with mild-to-moderate AD. However, there is a need for the discovery of more effective compounds and for this reason, plants can still be a potential source of new AChE-I. Findings and advances in knowledge about natural alkaloids as potential new drugs acting as AChE-I will be summarized in this paper.

Keywords: quinolizidine, steroidal, indole, isoquinoline

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]